colfosceril-palmitate and dipalmitoylphosphatidylcholine--hexadecanol--tyloxapol-drug-combination

colfosceril-palmitate has been researched along with dipalmitoylphosphatidylcholine--hexadecanol--tyloxapol-drug-combination* in 2 studies

Reviews

2 review(s) available for colfosceril-palmitate and dipalmitoylphosphatidylcholine--hexadecanol--tyloxapol-drug-combination

ArticleYear
Lucinactant: in neonatal respiratory distress syndrome.
    Treatments in respiratory medicine, 2005, Volume: 4, Issue:2

    Lucinactant, formerly known as KL(4) surfactant, is a novel synthetic lung surfactant containing phospholipids and an engineered peptide, sinapultide, which is designed to mimic the actions of human surfactant protein B. It has been developed for use in the prevention or treatment of respiratory distress syndrome (RDS), a common problem in premature infants, which results from a deficiency or degradation of pulmonary surfactant. Lucinactant is administered intratracheally soon after birth as a replacement surfactant. In the pivotal randomized, double-blind, prophylaxis trial in premature infants, the incidence of RDS at 24 hours after birth was significantly lower in lucinactant recipients than in recipients of colfosceril palmitate, a synthetic non-protein-containing surfactant. RDS-related mortality at 14 days was significantly lower in lucinactant recipients than in recipients of colfosceril palmitate or beractant, a bovine-derived surfactant. In another randomized, double-blind, prophylaxis trial in premature infants, the rate of survival without bronchopulmonary dysplasia at 28 days of age in lucinactant recipients was not inferior to that in recipients of poractant alfa, a porcine-derived surfactant. Lucinactant was generally well tolerated. Adverse events were transient and related to the administration procedure. There were no differences in the incidences of complications of prematurity between lucinactant and the other surfactants.

    Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Animals, Newborn; Biological Products; Drug Combinations; Fatty Alcohols; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intercellular Signaling Peptides and Proteins; Peptides; Phospholipids; Phosphorylcholine; Polyethylene Glycols; Pulmonary Surfactants; Respiratory Distress Syndrome; Surface Tension; Treatment Outcome

2005
Exogenous surfactant use in neonates.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:4

    To review exogenous surfactant use in the treatment of respiratory distress syndrome (RDS) in premature neonates.. A MEDLINE search and extensive review of journals was conducted to identify the information for this review from 1983 to 1995 using the following key words: prematurity, surfactant, clinical trials, beractant, Survanta, colfosceril, Exosurf, and neonatal respiratory distress syndrome.. All articles were considered for possible inclusion in the review. Emphasis was placed on controlled studies involving beractant and colfosceril palmitate.. Results of published clinical trials using beractant or colfosceril palmitate in premature infants at risk for RDS have shown improvement in the need for supplemental oxygen and ventilatory support over the course of RDS and a reduction in pneumothorax. However, there was little impact on the incidence of intraventricular hemorrhage. Clinical trials studying the treatment of established RDS have also shown similar improvements. In a comparison of prophylactic versus late treatment, no distinct advantage of preventive treatment was found, except among infants less than 26-28 weeks gestation. Single versus multiple-dose studies have shown no specific advantage of more than two doses of colfosceril palmitate. A comparison trial of beractant and colfosceril palmitate has shown no difference in outcome. Long-term follow-up studies have been encouraging among infants being treated with exogenous surfactant.. The use of beractant and colfosceril palmitate in premature infants has clearly decreased morbidity and mortality associated with RDS. Only one trial has compared the efficacy of beractant with that of colfosceril in the treatment of RDS. There does not appear to be a distinct advantage of one product over another. Early treatment of infants at highest risk for RDS, those less than 26-28 weeks gestation, seems to be beneficial over waiting for RDS to progress in severity. Further research needs to be performed to determine the optimal dosing and timing of these agents, as well as comparative trials studying efficacy. Criteria for use of these products need to be further defined to decrease the incidence of unnecessary treatment.

    Topics: 1,2-Dipalmitoylphosphatidylcholine; Biological Products; Drug Combinations; Fatty Alcohols; Humans; Infant, Newborn; Phosphorylcholine; Polyethylene Glycols; Pulmonary Surfactants; Respiratory Distress Syndrome, Newborn

1996

Trials

1 trial(s) available for colfosceril-palmitate and dipalmitoylphosphatidylcholine--hexadecanol--tyloxapol-drug-combination

ArticleYear
Exogenous surfactant use in neonates.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:4

    To review exogenous surfactant use in the treatment of respiratory distress syndrome (RDS) in premature neonates.. A MEDLINE search and extensive review of journals was conducted to identify the information for this review from 1983 to 1995 using the following key words: prematurity, surfactant, clinical trials, beractant, Survanta, colfosceril, Exosurf, and neonatal respiratory distress syndrome.. All articles were considered for possible inclusion in the review. Emphasis was placed on controlled studies involving beractant and colfosceril palmitate.. Results of published clinical trials using beractant or colfosceril palmitate in premature infants at risk for RDS have shown improvement in the need for supplemental oxygen and ventilatory support over the course of RDS and a reduction in pneumothorax. However, there was little impact on the incidence of intraventricular hemorrhage. Clinical trials studying the treatment of established RDS have also shown similar improvements. In a comparison of prophylactic versus late treatment, no distinct advantage of preventive treatment was found, except among infants less than 26-28 weeks gestation. Single versus multiple-dose studies have shown no specific advantage of more than two doses of colfosceril palmitate. A comparison trial of beractant and colfosceril palmitate has shown no difference in outcome. Long-term follow-up studies have been encouraging among infants being treated with exogenous surfactant.. The use of beractant and colfosceril palmitate in premature infants has clearly decreased morbidity and mortality associated with RDS. Only one trial has compared the efficacy of beractant with that of colfosceril in the treatment of RDS. There does not appear to be a distinct advantage of one product over another. Early treatment of infants at highest risk for RDS, those less than 26-28 weeks gestation, seems to be beneficial over waiting for RDS to progress in severity. Further research needs to be performed to determine the optimal dosing and timing of these agents, as well as comparative trials studying efficacy. Criteria for use of these products need to be further defined to decrease the incidence of unnecessary treatment.

    Topics: 1,2-Dipalmitoylphosphatidylcholine; Biological Products; Drug Combinations; Fatty Alcohols; Humans; Infant, Newborn; Phosphorylcholine; Polyethylene Glycols; Pulmonary Surfactants; Respiratory Distress Syndrome, Newborn

1996